<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00720577</url>
  </required_header>
  <id_info>
    <org_study_id>FHT-P-05-005</org_study_id>
    <nct_id>NCT00720577</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of Simvastatin, Losartan and Pioglitazone on Patients With Peripheral Arterial Disease.</brief_title>
  <acronym>LEAP</acronym>
  <official_title>Two-Part,Multicenter,Randomized,Double-Blind,Placebo-Controlled,Study to Evaluate the Effect of Simvastatin,Losartan,and Pioglitazone on Cardiovascular Disease Biomarkers in Lower Extremity Atherosclerotic Plaque Excised From Patients w/PAD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Endovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FoxHollow Technologies</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medtronic Endovascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part A. The purpose of this study is to assess the effects of 6 weeks of treatment with,&#xD;
      simvastatin, losartan or pioglitazone compared to placebo on the RNA expression profile of&#xD;
      lower extremity peripheral arterial atherosclerotic plaque. Part B. The effect of&#xD;
      simvastatin, losartan or pioglitazone compared to placebo on protein and lipid biomarkers in&#xD;
      lower extremity peripheral arterial atherosclerotic plaque.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, randomized, double-blind, placebo-controlled, 6 week study. The study&#xD;
      consists of 3 separate sub-studies in which patients undergoing bilateral lower extremity&#xD;
      peripheral artery atherectomy will receive one of three FDA approved drugs known to have&#xD;
      beneficial effect on the risk of cardiovascular disease. Patients will be selected for the&#xD;
      particular sub-study based on a series of entry criteria and then randomized to the&#xD;
      particular agent or placebo for 6-weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate RNA expression profiles, protein and lipid biomarkers, and gene expression profiling on pts receiving simvastatin, losartan or pioglitazone.</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate plaque characteristics in 3 patient subsets and Left and Right extremity comparisons.</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">164</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>40 Mg. tablet, 1 tablet daily</description>
    <arm_group_label>1</arm_group_label>
    <other_name>HMG-CoA reductase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>50 mg., tablets, 1 tablet once daily</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Cozaar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>30 mg, tablet, 1 tablet once daily</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Systematic (IUPAC)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women =90 years of age.&#xD;
&#xD;
          -  Bilateral lower extremity PAD requiring revascularization. Both extremities must have&#xD;
             at least 1denovo atherosclerotic lesion&#xD;
&#xD;
          -  Able to space bilateral atherectomy procedures by at least 6 weeks.&#xD;
&#xD;
          -  Willing to provide informed consent to participation in genetic studies.&#xD;
&#xD;
          -  Simvastatin Substudy&#xD;
&#xD;
          -  LDL-C &gt;100 mg/dL and &lt;250 mg/dL TG&lt;350 mg/dL&#xD;
&#xD;
          -  Not currently receiving or having taken a statin (simvastatin, lovastatin,&#xD;
             rosuvastatin, atorvastatin, or pravastatin) or a combination product containing a&#xD;
             statin for the previous 3 months.&#xD;
&#xD;
          -  Losartan Substudy&#xD;
&#xD;
          -  Diagnosis of hypertension with systolic blood pressure &gt;120 mm Hg but &lt;160 mm Hg, and&#xD;
             diastolic blood pressure &gt;80 mm Hg but &lt;100 mm Hg.&#xD;
&#xD;
          -  Not currently receiving or having taken an ACEi or ARB.&#xD;
&#xD;
          -  Pioglitazone Substudy&#xD;
&#xD;
          -  Type II diabetes mellitus&#xD;
&#xD;
          -  HbA1c &gt;5.5% and &lt; 8.5%&#xD;
&#xD;
          -  Otherwise on a stable glucose lowering regimen where no changes are expected in oral&#xD;
             regimen, or where no changes in insulin doses of more than 10 U are expected.&#xD;
&#xD;
          -  Not currently receiving or having taken a thiazolidinedione (rosiglitazone or&#xD;
             pioglitazone) or a combination product containing a thiazolidinedione or the previous&#xD;
             12 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is pregnant, breast-feeding, or expecting to conceive during the study&#xD;
             including the 14-day post study follow-up.&#xD;
&#xD;
          -  current condition, therapy, lab abnormality, mental legal incapacitation that in the&#xD;
             investigator's judgment might confound the results of the study.&#xD;
&#xD;
          -  Patient is currently participating in or has participated in a study with an&#xD;
             investigational compound within 30 days of Visit 1.&#xD;
&#xD;
          -  Patient has donated and/or received blood (including phlebotomy of &gt;300 mL) within 2&#xD;
             months prior to study.&#xD;
&#xD;
          -  Surgery or significant trauma within 2 months prior to Visit 1.&#xD;
&#xD;
          -  Patient is a user of recreational or illicit drugs or has had a recent history &lt;1yr&#xD;
             drug/alcohol abuse&gt;2 alcoholic drinks per day).&#xD;
&#xD;
          -  Patient was &lt;80% compliant with dosing during the placebo run-in period AND, in the&#xD;
             opinion of the investigator, believed to be unable to maintain at least an 80%&#xD;
             compliance with dosing during the active study dosing period.&#xD;
&#xD;
          -  Patient has history of myocardial infarction, stroke, coronary artery bypass surgery&#xD;
             or other coronary, carotid, or cerebral revascularization procedure,unstable angina,&#xD;
             or angioplasty within 1 month of Visit 1. - Patient has chronic heart failure defined&#xD;
             by New York Heart Association NYHA) Classes III or IV.&#xD;
&#xD;
          -  Known clinically significant AV conduction disturbances or arrhythmias&#xD;
&#xD;
          -  Patient has unstable hypertension (e.g., sitting systolic blood pressure &gt;160 mm Hg or&#xD;
             diastolic &gt;100 mm Hg) at Visit 1.&#xD;
&#xD;
          -  Any known clinically important bleeding or platelet disorder.&#xD;
&#xD;
          -  Patient has history of ileal bypass, gastric bypass, other significant condition&#xD;
             associated with malabsorption.&#xD;
&#xD;
          -  Patient is HIV or hepatitis B positive.&#xD;
&#xD;
          -  Patients with significantly elevated TSH at Visit 1 may be entered after consultation&#xD;
             with and approval by the SPONSOR. Patients with a history of hypothyroidism, who are&#xD;
             on a stable dose of thyroxine with normal TSH level at Visit 1 may be included.&#xD;
&#xD;
          -  Patients on cyclical estrogen medications (Estrogen Replacement Therapy ERT] or oral&#xD;
             contraceptives). Patients on non-cyclical estrogen replacement therapy or Selective&#xD;
             Estrogen Receptor Modulator (SERM) may be included, but must be on a stable dose for&#xD;
             at least 8 weeks prior.&#xD;
&#xD;
          -  Patients with active neoplastic disease which compromises their general health, or who&#xD;
             currently require chemotherapy or radiation therapy, or who have completed&#xD;
             chemotherapy or radiation therapy within 3 months prior.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Kandzari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <verification_date>July 2008</verification_date>
  <study_first_submitted>July 21, 2008</study_first_submitted>
  <study_first_submitted_qc>July 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2008</study_first_posted>
  <last_update_submitted>May 12, 2021</last_update_submitted>
  <last_update_submitted_qc>May 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peripheral Arterial Disease</keyword>
  <keyword>PAD</keyword>
  <keyword>Lower extremity peripheral arterial atherosclerotic plaque</keyword>
  <keyword>RNA Expression</keyword>
  <keyword>Lipid Biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

